Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 46.69% is in line with its 5-year average of 49.67%, around the middle of its 5-year range (44.09%–52.49%).
0.70% above its 12-month average of 46.37%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 49.61%.
GROSS MARGIN
46.69%
GROSS MARGIN AVG TTM
46.37%
GROSS MARGIN AVG 3Y
48.32%
GROSS MARGIN AVG 5Y
49.67%
GROSS MARGIN AVG 10Y
48.29%
GROSS MARGIN AVG 15Y
46.97%
GROSS MARGIN AVG 20Y
46.70%
CURRENT VS TTM AVG
+0.70%
CURRENT VS 3Y AVG
-3.38%
CURRENT VS 5Y AVG
-5.99%
CURRENT VS 10Y AVG
-3.31%
CURRENT VS 15Y AVG
-0.60%
CURRENT VS 20Y AVG
-0.03%
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 512 covered companies
CURRENT VS SECTOR MEDIAN
-1.05%
vs the sector median at left
Bruker Corporation
Market Cap
$9.57B
Gross Margin
46.69%
TTM Avg
46.37%
3Y Avg
48.32%
5Y Avg
49.67%
Market Cap
$8.97B
Gross Margin
101.98%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$9.76B
Gross Margin
30.31%
TTM Avg
29.43%
3Y Avg
29.32%
5Y Avg
29.12%
Market Cap
$8.98B
Gross Margin
93.24%
TTM Avg
91.97%
3Y Avg
90.98%
5Y Avg
60.65%
Market Cap
$10.00B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.75B
Gross Margin
100.00%
TTM Avg
-161.83%
3Y Avg
-33.28%
5Y Avg
-5.52%
Market Cap
$9.78B
Gross Margin
93.34%
TTM Avg
92.85%
3Y Avg
69.90%
5Y Avg
46.60%
Market Cap
$9.08B
Gross Margin
69.66%
TTM Avg
54.89%
3Y Avg
42.48%
5Y Avg
46.51%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bruker Corporation (BRKRP) | $9.57B | 46.69% | 46.37% | 48.32% | 49.67% |
| Insulet Corp. (PODD)vs › | $9.37B | 71.08% | 70.71% | 67.87% | 67.39% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.97B | 101.98% | 100.00% | 100.00% | 100.00% |
| Henry Schein, Inc. (HSIC)vs › | $9.76B | 30.31% | 29.43% | 29.32% | 29.12% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.98B | 93.24% | 91.97% | 90.98% | 60.65% |
| Bruker Corporation (BRKR)vs › | $10.00B | 46.69% | 47.45% | 49.39% | 49.15% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.75B | 100.00% | -161.83% | -33.28% | -5.52% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.78B | 93.34% | 92.85% | 69.90% | 46.60% |
| Caris Life Sciences, Inc. (CAI)vs › | $9.08B | 69.66% | 54.89% | 42.48% | 46.51% |
| The Ensign Group, Inc. (ENSG)vs › | $9.95B | 14.14% | 15.74% | 16.11% | 16.54% |
Gross Margin
46.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 49.61% |
| 2026-03-31 | 47.28% |
| 2025-12-31 | 45.97% |
| 2025-09-30 | 44.09% |
| 2025-06-30 | 44.88% |
| 2025-03-31 | 48.81% |
| 2024-12-31 | 50.36% |
| 2024-09-30 | 48.45% |
| 2024-06-30 | 48.03% |
| 2024-03-31 | 48.88% |
| 2023-12-31 | 50.36% |
| 2023-09-30 | 51.53% |
| 2023-06-30 | 49.93% |
| 2023-03-31 | 52.49% |
| 2022-12-31 | 51.62% |
| 2022-09-30 | 52.45% |
| 2022-06-30 | 50.90% |
| 2022-03-31 | 51.53% |
| 2021-12-31 | 50.26% |
| 2021-09-30 | 50.75% |
| 2021-06-30 | 49.21% |
| 2021-03-31 | 50.44% |
| 2020-12-31 | 50.28% |
| 2020-09-30 | 48.69% |
| 2020-06-30 | 43.03% |
| 2020-03-31 | 45.54% |
| 2019-12-31 | 49.59% |
| 2019-09-30 | 48.72% |
| 2019-06-30 | 47.00% |
| 2019-03-31 | 46.53% |
| 2018-12-31 | 49.28% |
| 2018-09-30 | 47.71% |
| 2018-06-30 | 46.25% |
| 2018-03-31 | 46.19% |
| 2017-12-31 | 48.11% |
| 2017-09-30 | 45.45% |
| 2017-06-30 | 44.20% |
| 2017-03-31 | 45.83% |
| 2016-12-31 | 46.86% |
| 2016-09-30 | 47.02% |
| 2016-06-30 | 45.76% |
| 2016-03-31 | 44.43% |
| 2015-12-31 | 44.23% |
| 2015-09-30 | 42.29% |
| 2015-06-30 | 42.78% |
| 2015-03-31 | 45.32% |
| 2014-12-31 | 42.48% |
| 2014-09-30 | 39.85% |
| 2014-06-30 | 43.83% |
| 2014-03-31 | 42.41% |
| 2013-12-31 | 42.73% |
| 2013-09-30 | 44.01% |
| 2013-06-30 | 44.32% |
| 2013-03-31 | 44.36% |
| 2012-12-31 | 46.82% |
| 2012-09-30 | 47.03% |
| 2012-06-30 | 44.73% |
| 2012-03-31 | 46.94% |
| 2011-12-31 | 45.82% |
| 2011-09-30 | 45.27% |
| 2011-06-30 | 45.76% |
| 2011-03-31 | 46.25% |
| 2010-12-31 | 47.37% |
| 2010-09-30 | 47.36% |
| 2010-06-30 | 45.10% |
| 2010-03-31 | 45.48% |
| 2009-12-31 | 50.63% |
| 2009-09-30 | 44.96% |
| 2009-06-30 | 44.04% |
| 2009-03-31 | 44.56% |
| 2008-12-31 | 48.60% |
| 2008-09-30 | 45.47% |
| 2008-06-30 | 41.32% |
| 2008-03-31 | 47.45% |
| 2007-12-31 | 46.61% |
| 2007-09-30 | 46.97% |
| 2007-06-30 | 43.58% |
| 2007-03-31 | 47.62% |
| 2006-12-31 | 46.58% |
| 2006-09-30 | 44.04% |
| 2006-06-30 | 43.63% |
| 2006-03-31 | 44.28% |
| 2005-12-31 | 41.54% |
| 2005-09-30 | 43.00% |
| 2005-06-30 | 42.80% |
| 2005-03-31 | 41.89% |
| 2004-12-31 | 34.83% |
| 2004-09-30 | 47.74% |
| 2004-06-30 | 40.61% |
| 2004-03-31 | 47.65% |
| 2003-12-31 | 43.14% |
| 2003-09-30 | 45.03% |
| 2003-06-30 | 46.76% |
| 2003-03-31 | 50.64% |
| 2002-12-31 | 52.74% |
| 2002-09-30 | 52.23% |
